06618 JD HEALTH
- 30.300
- -0.650-2.10%
JD HEALTH News
JD Health (06618) issues 350,000 shares under the initial public offering after-sale share incentive plan
JD Health (06618) issued an announcement on May 17, 2024, as adopted on November 2, 2020...
[Hong Kong Stock Connect] JD Health (06618) turned 2.58%. Non-IFRS operating profit fell 34.8% in the first quarter
Jinwu Financial News | JD Health (06618) fluctuated and declined. It once rose more than 2.4% in early trading and fell as low as 3.07% in the afternoon. As of press release, it was reported at HK$30.15, still down 2.58%, with a turnover of HK$236 million. JD Health announced that for the three months ended March 31, 2024, non-IFRS operating profit was 754 million yuan (RMB, same below), a year-on-year decrease of 34.8%; operating profit of 487 million yuan, a decrease of 38.7%; and revenue of 13.267 billion yuan, a decrease of 4.9%.
JD Health (06618) Announces First Quarter Results Non-IFRS Operating Profit Reaches 754 Million Yuan
According to the Zhitong Finance App, JD Health (06618) announced results for the first quarter of 2024, with revenue of about 13.267 billion yuan, operating profit of about 487 million yuan, and non-IFRS operating profit of about 754 million yuan. In the first quarter of 2024, a number of new specialty drugs were launched at Jingdong Pharmacies; including Loctec (remegipan sulfate tablets), a new drug for targeted migraine treatment by Pfizer, and Xilida (rosulvastatin ezetimib tablets), a new combined fat-reducing drug under Sanofi. The company also continues to deepen cooperation with pharmaceutical companies such as Shanghai Pharmaceutical, Daiichi Sankyo, and Mandi Pharmaceutical to further strengthen it
2023 年度報告
JD.com's 1Q Revenue Likely Supported by Low-Price Strategy, Better User Experience -- Market Talk
JD.com's low-price strategy and user experience enhancement likely sustained its gross merchandise value growth momentum and supported 1Q revenue growth, Daiwa analysts John Choi and Robin Leung say in a research note.
[Broker Focus] Tianfeng Securities maintains JD Health (06618) “buy” rating and is optimistic about the continued penetration of active users and the guarantee of omni-channel supply chain capabilities
Jinwu Financial News | According to Tianfeng Securities Research, JD Health (06618) achieved operating revenue of 53.5 billion yuan in 2023, an increase of 14.5% over 46.7 billion yuan in the same period last year; by business, the company's own product revenue in 2023 was 45.65 billion yuan, up 13.1% year on year; service revenue was 7.88 billion yuan, up 23.7% year on year. The company's gross margin increased by 1.0 pct to 22.2%, mainly due to changes in the product portfolio; annual profit was 2.14 billion yuan, up 459.2% year on year, and adjusted non-IFRS net profit reached 4.14 billion yuan, compared with 2
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
05:00 AM EDT, 03/22/2024 (MT Newswires) -- Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy Price (HKD): $28.05, Change: $-4.05, Percent Change: -12.62%
JD Health's 2023 Profit Soars Almost Sixfold to Over 2 Billion Yuan
JD Health International (HKG:6618) recorded a nearly sixfold surge in attributable profit for the year ended Dec. 31, 2023, to 2.14 billion yuan from 380.1 million yuan in 2022, a Wednesday filing on
[Hong Kong Stock Connect] JD Health (06618)'s profit of RMB 2,142 billion last year increased 463.49% year over year
Jinwu Financial News | JD Health (06618) announced that in 2023, the company's shareholders should account for profit of RMB 2,142 billion, an increase of 463.49% over the previous year; basic profit per share was 0.69 yuan. During the period, the company's revenue increased 14.5% from RMB 46.7 billion in 2022 to RMB 53.5 billion in 2023. In detail, the increase in the company's total revenue is mainly due to a 13.1% increase in product revenue from sales of pharmaceuticals and health products from RMB 40.4 billion in 2022 to RMB 45.7 billion in 2023. The main drivers for the growth of commodity revenue are
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health (06618) announced annual results, profit attributable to shareholders of 2.42 billion yuan, a sharp increase of 463.49% year-on-year, and the average number of online consultations throughout the year has exceeded 450,000
JD Health (06618) announced its annual results for the year ended December 31, 2023. The group will take...
JD HEALTH-R: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
JD HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
In 2024, what areas will JD Health focus on?
Sina Technology News On the afternoon of March 12, JD Health CEO Jin Enlin said at the 4th JD Health Partners Conference that in 2023, JD Health will further strengthen infrastructure construction, promote business innovation and experience upgrading, and continue to consolidate the “first entrance to online health consumption” advantage.
JD Health (06618.HK) plans to hold a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 JD Health (06618.HK) announced that the company will hold a board meeting on March 20, 2024 (Wednesday) to approve (among other things) the results of the company and its subsidiaries for the year ended 31 December 2023 and consider the proposed payment of a final dividend (if any). The Company's management will hold a conference call on March 21, 2024 (Thursday) at 9:30 a.m. (Beijing/Hong Kong time) to discuss the financial results of the Company and its subsidiaries for the year ended 31 December 2023.
JD HEALTH-R: DATE OF BOARD MEETING
JD HEALTH: DATE OF BOARD MEETING
CICC: Maintaining JD Health's “Outperforming Industry” Rating Target Price of HK$41.2
CICC released a research report stating that maintaining the JD Health (06618) “outperforming the industry” rating, considering the frequent influenza situation in various regions starting in 4Q23, it is expected to increase the 2023 profit forecast by 2% to 1.8 billion yuan. The 2024/2025 profit forecast remains unchanged, with a target price of HK$41.2. The bank expects the company's revenue side to achieve a year-on-year growth rate of about 15% in 2023. CICC's main views are as follows: It is expected that overall growth may be steady in 2023. 1-3Q23 achieved revenue of 38.696 billion yuan (+25
CICC: Maintaining JD Health's (06618) “Outperform the Industry” rating target price of HK$41.2
CICC expects JD Health (06618) to achieve a year-on-year growth rate of about 15% on the revenue side in 2023.
Analysis
Price Target
No Data
